Bentley Pharmaceuticals Named to Deloitte's 2006 Technology Fast 500 for the Second Year in a Row

EXETER, N.H., Oct. 19 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. , a specialty pharmaceutical company, today announced that it has been named number 430 on Deloitte's 2006 Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. To determine the fastest growing companies, Deloitte calculated the revenue growth percentage over five years (2001 - 2005). Bentley Pharmaceuticals has achieved this accomplishment for the second consecutive year.

"Bentley is a truly differentiated specialty pharmaceutical company with a hybrid business model that delivers steady revenue growth while reaching for higher margin, faster growth opportunities. We credit our growth over the past few years to our unique business model," said John Sedor, president of Bentley. "This growth also pays tribute to the talent and hard work of our employees. I applaud their hard work and look forward to the future success of our company."

"Sustaining high revenue growth over five years is an exceptional accomplishment. We commend Bentley Pharmaceuticals for making the commitment to technology and delivering on the promise of market longevity," said Tony Kern, deputy managing principal of Deloitte's Technology, Media & Telecommunications industry practice. "We are proud to honor Bentley Pharmaceuticals ranking on the Deloitte Technology Fast 500 list."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API. Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at http://www.bentleypharm.com/.

Contact: Bentley Pharmaceuticals, Inc. Jean DeRoche 603.658.6136